



**Office of Vermont Health Access  
Pharmacy Benefits Management Program  
DUR Board Meeting Agenda**

---

**December 8, 2009 6:30 – 9:00 p.m.**

- 1. Executive Session** **6:30 - 7:00**
  - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
  
- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**  
(Public Comment Prior to Board Action)
  
- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**
  
- 4. Medical Director Update** **7:15 - 7:20**
  - Clinical Programs Update
  - Prescriber Comments
  
- 5. Follow-up Items from Previous Meeting** **7:20 - 7:25**
  - Vectical<sup>®</sup> (calcitriol) Topical Ointment
  
- 6. Clinical Update: Drug Reviews** **7:25 – 7:45**  
(Public comment prior to Board action)
  - Abbreviated New Drug Reviews**
    - Fibracor<sup>®</sup> (fenofibric acid) Tablet
    - Zipsor<sup>®</sup> (diclofenac potassium) Capsule
  
  - Full New Drug Reviews**
    - Besivance<sup>®</sup> (besifloxacin) Ophthalmic Suspension
    - Samsca<sup>®</sup> (tolvaptan) Tablet
  
- 7. Drug Classes – Annual Review** **7:45 – 8:40**  
(with selected new drug or new drug dosage form reviews)  
(Public comment prior to Board action)  
**Class review documents available on OVHA web site 12/08/09 @ 12 Noon**
  - Androgens including Topical Testosterone Products
  - Anticonvulsants (including abbreviated review of Lamictal<sup>®</sup> (lamotrigine) ODT, Lamictal<sup>®</sup> (lamotrigine)XR, Sabril<sup>®</sup> (vigabatrin) and Vimpat<sup>®</sup> (lacosamide))
  - Antipsychotics (including abbreviated review of Invega<sup>®</sup> Sustenna (paliperidone palmitate IM ER and Saphris<sup>®</sup> (asenapine maleate))
  - Benign Prostatic Hyperplasia (BPH) Treatments (Alpha Blockers and Androgen Hormone Inhibitors)
  - Urinary Antispasmodics (including abbreviated review of Gelnique<sup>®</sup> (oxybutynin) gel)
  
- 8. RetroDUR/Quality Assurance Analysis** **8:40 - 8:50**
  - Xolair<sup>®</sup> (omalizumab) for persistent asthma
  
- 9. Updated New-to-Market Drug Monitoring Log (Consent Agenda Topic)**
  - Now on OVHA website **8:50 - 8:50**

**10. General Announcements**

**8:50 – 8:55**

**Selected FDA Safety Alerts**

- Meridia<sup>®</sup> (sibutramine hydrochloride): Early communication about an ongoing safety review
- Clopidogrel and Omeprazole – Drug interaction

**11. Adjourn**

**9:00**